Quality Assessment in Multiple Sclerosis Therapy (QUASIMS)-Reference-Cited by-同舟云学术

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS)

Published:2007-01 Issue:1 Volume:254 Page:67-77
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Limmroth Volker,Malessa Rolf,Zettl Uwe Klaus,Koehler Jürgen,Japp Gudrun,Haller Peter,Elias Wolfgang,Obhof Winfried,Viehöver Andrea,Meier Uwe,Brosig Arne,Hasford Joerg,Putzki Norman,Kalski Gabriele,Wernsdörfer Colin,

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

http://link.springer.com/content/pdf/10.1007/s00415-006-0281-1.pdf

Reference27 articles.

1. Durelli L, Verdun E, Barbero P, et al. (2002) Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359:1453–1460

2. Haas J, Firzlaff M, Schmidt M (2005) Twenty-four-month comparison of immunomodulatory agents – a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate. Eur J Neurol 12:425–431

3. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655–661

4. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1996) Neutralizing antibodies during treatment of multiple sclerosis with interferon beta 1-b: experience during the first three years. Neurology 47:889–894

5. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45:1277–2385

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Do efficacy results obtained from randomized controlled trials translate to effectiveness data from observational studies for relapsing–remitting multiple sclerosis?;Pharmacoepidemiology and Drug Safety;2024-05

2. Standard Dose Weekly Intramuscular Beta Interferon-1a May Be Inadequate for Some Patients with Multiple Sclerosis: A 19-Year Clinical Experience Using Twice a Week Dosage;Neurology and Therapy;2022-07-07

3. Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS;Frontiers in Neurology;2021-01-12

4. Multiple sclerosis (MS) is autoimmune disorder affecting the central nervous system;Neurologie pro praxi;2020-06-18

5. Tolerability, treatment satisfaction and quality of life outcomes in stable multiple sclerosis patients switched from injectable therapies to auto injected intramuscular interferon beta 1a: The SFERA study;Multiple Sclerosis and Related Disorders;2019-05